HDAC inhibitor

Related by string. HDAC inhibitors * HDACs : HDAC inhibition . oral isoform selective HDAC . MGCD# fungal Hos2 HDAC . using MethylGene HDAC / Inhibitor . Inhibitors . inhibitors : proton pump inhibitors . proton pump inhibitors PPIs . ACE inhibitors * histone deacetylase HDAC inhibitor . histone deacetylase HDAC inhibitors . pan HDAC inhibitor . selective HDAC inhibitors *

Related by context. All words. (Click for frequent words.) 72 kinase inhibitor 70 MEK inhibitors 69 HDAC Inhibitor 68 orally bioavailable 67 ENMD # 67 targeting CD# 67 orally administered inhibitor 67 small molecule inhibitor 67 investigational humanized monoclonal antibody 67 kinase inhibitors 67 Perifosine 67 selective kinase inhibitor 66 JAK inhibitor 66 histone deacetylase HDAC inhibitor 66 HDACi 66 PI3K inhibitor 66 histone deacetylase inhibitor 66 humanized monoclonal antibody 66 selective inhibitor 66 CYC# 66 oral prodrug 65 anti angiogenic 65 novel histone deacetylase 65 proteasome inhibitors 65 Hsp# inhibitors 65 polymerase inhibitor 65 PI3K/mTOR 65 PARP inhibitor 65 vascular disrupting agents 65 Aurora kinase 65 JAK1 65 OXi# 65 MEK inhibitor 65 PNP inhibitor 65 Factor VIIa 65 PXD# 65 multi kinase inhibitor 64 HDAC inhibitors 64 AKT inhibitor 64 mTOR inhibitor 64 Bortezomib 64 polymerase inhibitors 64 anti angiogenic agent 64 JAK inhibitors 64 small molecule inhibitors 64 pertuzumab 64 oral antiviral 64 PSN# [002] 64 ARRY # 64 Azedra 64 HDAC 64 inhibitor 64 angiogenesis inhibitor 64 PDE4 inhibitor 64 induce apoptosis 63 potent inhibitor 63 obatoclax 63 receptor tyrosine kinase inhibitor 63 proteasome inhibitor 63 MGCD# [001] 63 rNAPc2 63 PI3K inhibitors 63 Kinase Inhibitor 63 orally dosed 63 HGS# 63 CCR9 63 anticancer agent 63 HCV protease 63 Carfilzomib 63 OMP #M# 63 IAP inhibitor 63 oncolytic 63 Onconase 63 pan HDAC inhibitor 63 antisense inhibitor 63 liposomal formulation 63 protein kinase inhibitor 63 highly selective inhibitor 63 poly ADP ribose polymerase 63 IMC A# 63 histone deacetylase HDAC 63 TLR8 63 vascular disrupting agent 63 radiation sensitizer 63 vidofludimus 63 AEG# 63 investigational compound 63 selective inhibitors 63 novel peptide 63 selective inhibition 62 HuLuc# 62 immunomodulator 62 Vidofludimus 62 small molecule 62 reversible inhibitor 62 alvespimycin 62 pro angiogenic 62 antitumor 62 VEGFR2 62 mertansine 62 Panzem R 62 Bezielle 62 perifosine 62 MGCD# [002] 62 immunomodulatory 62 cyclin dependent kinase inhibitor 62 Preclinical studies suggest 62 Archexin 62 sodium glucose cotransporter 62 anti fibrotic 62 xenograft models 62 delta isoform 62 histone deacetylase 62 Bafetinib 62 selective agonist 62 anticancer agents 62 SERMs 62 PI3 kinase 62 milatuzumab 62 BAY #-# 62 THR beta agonist 62 nucleoside analog 62 molecularly targeted 62 Cloretazine R 62 DNA intercalator 62 Xanafide 62 Blinatumomab 62 solid tumors 62 oxidative stress inducer 62 geldanamycin 62 antitumor activity 62 anticancer therapies 62 Tyrima 62 imetelstat 62 ENMD 62 CYT# potent vascular disrupting 62 preclinical models 62 VEGF receptor 61 tyrosine kinase inhibitor 61 PTP 1B 61 Panzem R NCD 61 IAP inhibitors 61 Aplidin 61 CA4P 61 mTOR inhibitors 61 HSP# inhibitor 61 selectively inhibits 61 Debio 61 XL# XL# 61 KSP inhibitor 61 Sym# 61 immune modulator 61 Pathway Inhibitor 61 isoform selective 61 kinase inhibition 61 demethylating agent 61 targeted radiotherapeutic 61 selective antagonist 61 MLN# 61 PKC# 61 Hsp# Inhibitor 61 MAb 61 CYT# 61 deforolimus 61 otelixizumab 61 agonist 61 enzyme inhibitor 61 depsipeptide 61 receptor agonist 61 Nanobody ® 61 humanized anti 61 non nucleoside 61 receptor antagonists 61 potently inhibit 61 signal transduction inhibitor 61 Inhibitor 61 MORAb 61 peptidomimetic 61 novel anticancer 61 IMA# 61 antisense oligonucleotide 61 JAK2 inhibitor 61 vorinostat 61 pro apoptotic 61 Symadex 61 selective immunoproteasome inhibitor 61 Ceflatonin 61 receptor agonists 61 R#/MEM # 61 Nanobody 61 Irinotecan 61 Guanilib 61 XmAb# 61 neuroprotective properties 61 Enzastaurin 61 Preclinical studies 61 TLR7 61 antisense inhibitors 61 Hsp# inhibition 61 BN# [002] 61 CD# monoclonal antibody 61 small molecule tyrosine 61 HGS ETR2 61 Aflibercept 61 ALK inhibitor 61 peripherally acting 61 AP# [003] 61 sphingosine 1 61 RNAi therapeutic targeting 61 CCX# 61 Smac mimetic 61 anticancer compound 61 CCR2 61 epothilone 61 Tarvacin TM 61 humanized antibody 61 chemopreventive agent 61 BRAF inhibitor 61 pan histone deacetylase 61 CEQ# 61 FLT3 61 erlotinib Tarceva ® 61 CCR5 antagonist 60 Cloretazine ® 60 Liposomal 60 effector function 60 preclinically 60 Dapagliflozin 60 LEX System 60 Imprime PGG 60 cyclophilin inhibitor 60 CRTH2 60 Daclizumab 60 IgG1 antibody 60 cyclin dependent kinases CDKs 60 HGS ETR1 60 ErbB3 60 CDK inhibitor 60 BAL# [001] 60 Squalamine 60 Seliciclib 60 Akt inhibitor 60 RAF kinase 60 EGFr 60 entinostat 60 PARP inhibitors 60 Hsp# inhibitor 60 PRT# 60 oral anticancer 60 Pradefovir 60 Denufosol 60 OncoVEX GM CSF 60 ganetespib 60 GRN#L 60 EZN 60 oral Factor Xa 60 Pralatrexate 60 p# mitogen activated 60 preclinical efficacy 60 NEUGENE 60 Angiolix 60 Anticalin 60 TRO# 60 immunotherapeutic 60 HCV protease inhibitor 60 huN# DM1 60 AQ4N 60 Omacetaxine 60 INCB# [001] 60 VEGF inhibitors 60 mitogen activated ERK kinase 60 histone deacetylase inhibitors 60 enzastaurin 60 CXCR4 60 tubulin inhibitor 60 MET VEGFR2 60 ATL/TV# 60 BZL# 60 oncolytic virus 60 anti CD3 60 cilengitide 60 HIV integrase inhibitor 60 immune stimulatory 60 Janus kinase 60 inhibitory effects 60 EGFR HER2 60 monoclonal antibody 60 NS4A 60 Azixa 60 HDAC enzymes 60 PI3K/Akt pathway inhibitor 60 Vandetanib 60 induces apoptosis 60 SARMs 60 cathepsin K inhibitor 60 potent anticancer 60 receptor antagonist 60 Pharmacokinetics PK 60 ProLindac 60 ADP receptor antagonist 60 HQK 60 Aurora Kinase 60 Proxinium TM 60 hematological cancers 60 Factor Receptor 60 targeted antifolate 60 vinca alkaloid 60 preclinical compounds 60 PEG SN# 60 ASONEP 60 alpha folate receptor 60 Voreloxin 60 p# inhibitor 60 AZD# 60 Romidepsin 60 JAK2 inhibitors 60 phosphatidylinositol 3 60 antitumor effects 60 JAK3 60 TG# [003] 60 Panzem 60 PEGylated Fab fragment 60 partial agonist 60 pharmacodynamic profile 60 investigational pan BCR 60 Epidermal Growth Factor Receptor 60 drug conjugate 60 VEGF receptors 60 novel immunomodulatory 60 phosphate S1P 59 BiTE 59 oral proteasome inhibitor 59 seliciclib CYC# 59 EOquin 59 Vicinium TM 59 E#F# 59 Cloretazine 59 AEZS 59 immunomodulating 59 Anticalin R 59 adenoviral 59 Gleevec resistant 59 novel orally administered 59 HepDirect prodrug 59 selective androgen receptor modulator 59 multitargeted 59 humanized monoclonal antibodies 59 TLR8 agonist 59 MTP inhibitor 59 IMiD 59 T#I [002] 59 Nexavar ® 59 Vorinostat 59 SCH # 59 cytoprotective 59 potently inhibited 59 mTOR 59 mTOR mammalian target 59 TREANDA 59 Traficet EN 59 ALN TTR 59 humanised antibody 59 romidepsin 59 chemokine receptor 59 IGF 1R 59 nicotinic alpha 7 59 MGd 59 PLX# 59 investigational therapies 59 siRNA therapeutics 59 Deforolimus 59 AAG geldanamycin analog 59 JAK#/JAK# 59 siRNA therapeutic 59 TAFA# 59 BMS # 59 GSK3B 59 Pertuzumab 59 tumor vascular disrupting 59 anticancer activity 59 potent antiproliferative 59 fusion protein 59 INGN 59 selective modulator 59 preclinical studies 59 forodesine 59 non nucleoside inhibitor 59 5 HT6 receptor 59 cancer immunotherapies 59 Kinases 59 tkRNAi 59 indibulin 59 renin inhibitors 59 small molecule activators 59 RGB # 59 Bruton tyrosine kinase 59 therapeutic monoclonal antibody 59 OHR/AVR# 59 Syk 59 #ME# 59 investigational oral 59 TLR agonists 59 small molecule activator 59 glucagon receptor 59 preclinical 59 peptide antigens 59 Aurora kinase inhibitor 59 PI3K Akt 59 Receptor Antagonist 59 hypoxia inducible factor 59 MT# MEDI 59 anticancer compounds 59 histone deacetylase HDAC inhibitors 59 Zolinza 59 A3 adenosine receptor 59 thrombin receptor 59 PF # [001] 59 specific protein tyrosine 59 R roscovitine 59 agonist compounds 59 DXL# 59 small molecule chemotherapeutic 59 glucocorticoid receptor 59 CTLA 4 59 NK1 59 bevacizumab Avastin ® 59 antitumoral 59 seliciclib 59 phosphoinositide 3 59 siRNAs targeting 59 P#X# 59 EGFR inhibitors 59 IMiDs R 59 Sphingomab 59 GAP #B# 59 subtype selective 59 CR# vcMMAE 59 Exelixis compounds 59 gemcitabine Gemzar ® 59 FK# 59 Hedgehog signaling pathway 59 Pazopanib 59 brostallicin 59 KSP inhibitors 59 OvaRex R 59 cyclin dependent kinase CDK 59 radiolabeled 59 murine monoclonal antibody 59 TLR9 agonist 59 estrogen receptor beta 59 oral formulation 59 PPARγ 59 Vascular Endothelial Growth 59 Protein Kinase C 59 HER1 59 oral JAK1 59 #HT#A 59 LHRH 59 antiangiogenic 59 Cloretazine R VNP#M 59 5 HT2A inverse 59 ARRY 59 Varespladib 59 HCV protease inhibitors 59 deacetylase 59 trodusquemine 59 Phase Ib 59 Epratuzumab 59 anti amnesic 59 oral kinase inhibitor 59 injectable formulation 59 Olaparib 59 chemotherapeutic agents 59 prodrug 58 adenosine A2A 58 Talabostat 58 ATL# [002] 58 Etoposide 58 visilizumab 58 sunitinib malate 58 tumor antigen 58 fosbretabulin 58 EGF receptor 58 phosphatases 58 small molecule Hedgehog 58 antisense drugs 58 oral isoform selective HDAC 58 BiTE antibody 58 synthetic peptide 58 docetaxel Taxotere R 58 small molecule defensin 58 NXL# 58 GLPG# 58 monoclonal antibody MAb 58 cytotoxic 58 axitinib 58 peroxisome proliferator activated 58 small molecule agonists 58 CBLC# 58 cortisol receptor 58 nab paclitaxel 58 tanespimycin 58 somatostatin analogue 58 amrubicin 58 Elesclomol 58 alkylating agent 58 eniluracil 58 Antisense 58 CD# antibody [001] 58 cytotoxicity 58 Mipomersen 58 LY# [002] 58 selective estrogen receptor 58 anticancer therapeutics 58 luteinizing hormone releasing 58 IGF IR 58 Janus Kinase 58 selective orally bioavailable 58 PPAR 58 DB# [003] 58 Personalized Immunotherapy 58 Glufosfamide 58 myeloma cells 58 HCV polymerase inhibitor 58 c MET 58 Afatinib 58 epothilones 58 favorable pharmacokinetic profile 58 Linaclotide 58 systemically administered 58 hepatoma 58 torezolid phosphate 58 fibrotic disease 58 antisense drug 58 Intravenous CP 58 essential thrombocythemia ET 58 prostanoid 58 sorafenib Nexavar 58 ATL# [001] 58 Hedgehog pathway 58 multikinase inhibitor 58 CD# [002] 58 solithromycin 58 dexpramipexole 58 sodium glucose transporter 58 AT1R 58 immunoregulatory 58 BCR ABL 58 hypoxia activated prodrug 58 investigational monoclonal antibody 58 elacytarabine 58 2 methoxyestradiol 58 INT# [002] 58 IgG1 monoclonal antibody 58 5 HT2A serotonin 58 anti secretory 58 selective adenosine 58 Fc fusion protein 58 fipamezole 58 irreversible inhibitor 58 mGluR2 NAM 58 Luteinizing Hormone Releasing Hormone 58 5 HT6 58 anti proliferative 58 Maribavir 58 PI3K 58 antibody fragment 58 Ocrelizumab 58 Phase Ib clinical trials 58 Sapacitabine 58 Ophthotech 58 interferon lambda 58 pomalidomide 58 Radezolid 58 NEUGENE antisense 58 SGLT2 58 TKB# 58 aurora kinase inhibitor 58 PEGylated 58 ErbB3 HER3 58 etoposide 58 metastatic colorectal 58 G CSF 58 CCR1 58 HDAC inhibition 58 NPC 1C 58 investigational drug 58 potently inhibits 58 muscarinic 58 Phase Ib clinical 58 N methyl 58 neratinib 58 intratumoral injection 58 resolvins 58 ENaC 58 talabostat 58 Kinase 58 Alpharadin 58 TRV# [001] 58 insulin sensitizer 58 ALV# 58 novel VDA molecule 58 Nedd4 58 paclitaxel Taxol 58 registrational trial 58 subcutaneous formulation 58 FOLOTYN ® 58 defensin mimetic antibiotic 58 AEGR 58 Wnt signaling pathway 58 inhaled formulation 58 apoptotic pathway 58 RH1 58 CORT # 58 sorafenib tablets 58 MAGE A3 ASCI 58 Pimavanserin 58 atacicept 58 pathophysiological effects 58 ADI PEG 58 Tarceva TM 58 XL# anticancer compounds 58 nicotinic acetylcholine receptor 58 Triapine 58 oxazolidinone 58 LHRH receptor positive 58 MET amplification 58 CCR9 antagonist 58 hematologic malignancies 58 belinostat 58 peptibody 58 Virulizin ® 58 insulin sensitizing 58 volociximab 58 IL #E 58 antisense inhibition 58 EpCAM 58 microtubule targeting 58 GPCR targets 58 tolerability profile 58 GMX# 58 Factor Xa inhibitor 58 FAAH 58 5 HT2A receptor 58 chemokine 58 M2 subunit 58 Bruton tyrosine kinase Btk 58 Kahalalide F 58 hormone LHRH antagonist 58 Fibroblast Growth Factor Receptor 58 Posiphen 58 deacetylase inhibitors 58 LHRH antagonist 58 TLR9 58 selectively inhibit 58 gastrin 58 serine protease 57 #D#C# 57 MVA BN R 57 ISIS # 57 androgen independent 57 thalidomide Thalomid 57 candidate deforolimus 57 lymphoid malignancies 57 paclitaxel poliglumex 57 Cytochrome P# 57 Receptor Antagonists 57 pharmacological chaperone 57 EGFR HER 57 REP# 57 MEK1 57 AMPK activators 57 PPARgamma 57 JVRS 57 LEP ETU 57 Lenalidomide 57 hedgehog pathway 57 Lenocta TM 57 hematological malignancies 57 Apaziquone 57 huC# DM4 57 LHRH antagonists 57 CD3 monoclonal antibody 57 Fleximer 57 prolyl hydroxylase inhibitors 57 antibody MT# 57 MUC1 57 gamma secretase inhibitor 57 mouse xenograft models 57 elotuzumab 57 Abl 57 protein kinase inhibitors 57 ErbB 57 HuMax EGFr 57 Presents Preclinical Data 57 antiproliferative activity 57 bendamustine 57 intravesical instillation 57 Survivin 57 BRAF kinase 57 anti leukemic 57 antiviral activity 57 Tesetaxel 57 epigenetic therapies 57 VA# [002] 57 tremelimumab 57 KRN# 57 Amplimexon 57 highly selective endothelin 57 tiapamil 57 TG# [001] 57 daclizumab 57 thymalfasin 57 Cintredekin Besudotox 57 dasatinib Sprycel 57 Phase Ib II 57 Tanespimycin 57 T DM1 57 Multimeric 57 antiangiogenic agent 57 Lixivaptan 57 ON #.Na 57 ARIKACE ™ 57 ixabepilone 57 antisense 57 protein tyrosine phosphatase 1B 57 myeloproliferative disorders 57 agent VDA 57 darinaparsin ZIO 57 Chemokine Receptor 57 murine 57 Darinaparsin 57 Tofacitinib 57 Smac mimetics 57 systemic RNAi therapeutic 57 non nucleoside HCV 57 cetuximab Erbitux R 57 SGLT2 inhibitor 57 small molecule glucokinase 57 CDDO Im 57 c Raf kinase 57 uPA 57 RNAi therapeutic 57 ocular formulation 57 NTDDS 57 mu opioid receptor antagonist 57 chemotherapeutic drug 57 ribonuclease 57 metaglidasen 57 inhibit tumor 57 gefitinib Iressa 57 antimetastatic 57 CB2 receptor 57 chemotherapeutic agent 57 novel topoisomerase 57 cytochrome P# 57 nucleoside 57 tamibarotene 57 GSK # 57 insulin sensitizers 57 fluoropyrimidine 57 Zoraxel TM 57 transgenic mouse model 57 PEG Interferon lambda 57 replicon 57 kinesin spindle protein 57 Tarvacin 57 castrate resistant prostate cancer 57 potent inhibition 57 cMET 57 HuMax CD4 57 LPA1 57 FGFR2 57 CXCR4 receptor 57 Tumor Necrosis Factor 57 ANG# 57 TGF ß 57 DepoVax 57 VNP#M 57 alpha7 57 IgG1 57 inverse agonist 57 CCR5 antagonists 57 Elvitegravir 57 erythropoietic 57 decitabine 57 AMD# [003] 57 Galectin 57 cutaneous T 57 Aliskiren 57 PDX pralatrexate 57 HDACs 57 GDIR 57 immunoconjugate 57 glioma cells 57 carfilzomib 57 nucleoside analogues 57 XYOTAX TM 57 tyrosine kinase receptor 57 demonstrated antitumor activity 57 IMC #B 57 mGluR5 antagonists 57 GRN# 57 CUDC 57 tezampanel 57 kinesin spindle protein KSP 57 enzyme inhibitors 57 flavopiridol 57 chemotherapeutics 57 vivo 57 Gefitinib 57 cholesteryl ester transfer 57 Marqibo 57 DOS# 57 immune modulating 57 EndoTAGTM 1 57 CB2 selective receptor agonist 57 farletuzumab 57 diarrhea predominant irritable 57 tolerability 57 Akt activation 57 imatinib Gleevec ® 57 potent antitumor activity 57 CD# expressing 57 antibody MAb 57 imatinib Gleevec 57 HER2 positive metastatic breast 57 uricase 57 Eg5 57 immunomodulatory therapy 57 VEGFR2 inhibitor 57 Exherin TM 57 veltuzumab 57 selective inverse agonist 57 thyroid hormone receptor 57 Phase 1b 57 therapeutic monoclonal antibodies 57 vitro studies 57 agonists 57 mda 7 57 ganaxolone 57 Atiprimod 57 Prodarsan ® 57 Aplidin R 57 MEK inhibitor RDEA# 57 CTCE 57 novel prodrug 57 Dasatinib 57 EP1 receptor 57 JUVISTA R Human 57 receptor inhibitor 57 CTLA4 Ig 57 oncogenic 57 anticoagulant reversing agent 57 vaccine adjuvant 57 mTOR kinase 57 FGFR 57 lintuzumab 57 aurora kinase 57 sunitinib Sutent ® 57 JAK2 Inhibitor 57 G Protein Coupled 57 VEGF Trap 57 ADAM# 57 mimetics 57 BioVant 57 Icatibant 57 phosphorylate 57 Cethrin R 57 superficial bladder cancer 57 TRC# 57 tubulin binding 57 neurotrophic 57 reslizumab 57 ONCONASE 57 orally administered 57 ZACTIMA 57 Phase #b/#a clinical 57 PDGF receptor 57 PRTX 57 cleavable linker 57 S1P 57 omacetaxine 57 resolvin 57 elesclomol 57 leukemic stem cells 57 Exelixis XL# 57 pharmacodynamic properties 57 personalized immunotherapy 57 2 inhibitor CYT# 57 mediated apoptosis 57 predictive biomarkers 57 Aclidinium 57 investigational 57 XL# inhibits 57 TELINTRA 57 aflibercept 57 cell lymphoma CTCL 56 immunotherapeutic vaccine 56 VQD 56 HER3 56 peptide conjugated 56 iSONEP 56 reversible inhibitors 56 molecularly targeted therapy 56 teplizumab 56 MT#/MEDI-# 56 c MYC 56 factor G CSF 56 Curaxin 56 lapatinib Tykerb 56 direct thrombin inhibitors 56 PLK1 SNALP 56 VitiGam 56 XL# XL# XL# XL# 56 Serdaxin 56 IRX 2 56 5 HT4 receptor 56 oral dihydropyrimidine dehydrogenase DPD 56 TRX1 56 vaccine GRNVAC1 56 nitric oxide donating 56 dihydrofolate reductase 56 fluoroquinolone antibiotic 56 Myocet 56 NS5b 56 phase IIa clinical 56 retinoic acid receptor 56 ERK1 2 56 ZK EPO 56 RDEA# 56 ProLindac TM 56 XL# XL# XL# 56 COX2 56 androgen receptor AR 56 Belinostat 56 CDK inhibitors 56 SGLT inhibitors 56 sapacitabine 56 anti angiogenesis 56 cyclin dependent kinase 56 mAb 56 cortisol synthesis 56 ZFP TF 56 rxRNA 56 cyclophilin inhibitors 56 Azacitidine 56 Reports Preclinical Data 56 Resten NG 56 daptomycin 56 dasatinib Sprycel ® 56 Amrubicin 56 chimeric monoclonal antibody 56 bexarotene 56 Annamycin 56 antisense oligonucleotides 56 TRAIL receptor 56 Nanobodies 56 Targretin 56 Doxorubicin 56 receptor blocker 56 integrase inhibitor 56 neuronal nitric oxide synthase 56 immunostimulatory 56 p# inhibitors 56 fusion proteins 56 small molecule modulators 56 reverse transcriptase inhibitors 56 mitotic kinesin 56 taxanes 56 relapsed refractory 56 Bavituximab 56 protein mTOR 56 RNA antagonist 56 Curaxins 56 inhibit replication 56 selective serotonin 2C receptor 56 topoisomerase 56 Initiate Phase 56 angiotensin receptor blocker ARB 56 stable nucleic acid 56 RANK Ligand 56 GV# [001] 56 ERK5 56 combinability 56 Cannabinor 56 IMGN# 56 safety tolerability pharmacokinetic 56 acadesine 56 PDE4 56 Oral NKTR 56 ANYARA 56 HIF PH inhibitors 56 novel antiviral therapeutics 56 TNF receptors 56 PKCi 56 CD4 monoclonal antibody 56 Myolimus 56 PCK#

Back to home page